• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    9/16/24 10:36:19 AM ET
    $DECA
    Blank Checks
    Finance
    Get the next $DECA alert in real time by email
    SC 13G/A 1 ea0214609-13ga1denalicap_den.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Denali Capital Acquisition Corp.

     

    (Name of Issuer)

     

    Class A Ordinary Shares, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    G6256B106

     

    (CUSIP Number)

     

    August 30, 2024

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
         
      ☐ Rule 13d-1(c)
         
      ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on the following pages

    Page 1 of 9 Pages

    Exhibit Index: Page 8

     

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No. G6256B106  

     

             
    1

    NAMES OF REPORTING PERSONS

     

    Denali Capital Global Investments LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,942,500

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,942,500

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,942,500

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (SEE INSTRUCTIONS)

     

    ☐ 

     
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    65.6%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    Page 2 of 7

     

     

    SCHEDULE 13G

     

    CUSIP No. G6256B106  

     

             
    1

    NAMES OF REPORTING PERSONS

     

    Jiandong Xu

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,942,500

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,942,500

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,942,500

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (SEE INSTRUCTIONS)

     

    ☐ 

     
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    65.6%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

     

    Page 3 of 7

     

     

    Item 1(a) Name of Issuer:

     

    Denali Capital Acquisition Corp. (the “Issuer”)

     

    Item 1(b) Address of Issuer’s Principal Executive Offices:

     

    437 Madison Avenue, 27th Floor

    New York, NY 10022

    United States

     

    Item 2(a) Name of Person Filing:

     

    This statement on Schedule 13G (“Statement”) is filed on behalf of each of the following persons (collectively, the “Reporting Persons”) by:

     

    (i) Denali Capital Global Investments LLC (the “Sponsor”), which serves as the sponsor to the Issuer; and

     

    (ii) Jiandong Xu (“Mr. Xu”), who serves as the manager and controlling member of the Sponsor.

     

    This Statement relates to the Class A Ordinary Shares (as defined herein) held directly by the Sponsor and which the Sponsor has the right to acquire upon conversion of Class B Ordinary Shares, par value $0.0001 per share (“Class B Ordinary Shares”). Mr. Xu, as the controlling member of the Sponsor, may be deemed to beneficially own the Class A Ordinary Shares directly beneficially owned by the Sponsor.

     

    Item 2(b) Address of Principal Business Office or, if None, Residence:

     

    The address of the business office of the Sponsor and Mr. Xu is:

     

    c/o Denali Capital Acquisition Corp.

    437 Madison Avenue, 27th Floor

    New York, NY 10022

    United States

     

    Item 2(c) Citizenship:

     

    The Sponsor is a company organized under the laws of the Cayman Islands. Mr. Xu is a citizen of the United States of America.

     

    Item 2(d) Title and Class of Securities:

     

    Class A Ordinary Shares, $0.0001 par value per share (“Class A Ordinary Shares”)

     

    Item 2(e) CUSIP No.:

     

    G6256B106

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    This Item 3 is not applicable.

     

    Page 4 of 7

     

     

    Item 4. Ownership

     

    (a) Amount beneficially owned:

     

    As of August 30, 2024, each of the Reporting Persons may be deemed the beneficial owner of 1,942,500 Class A Ordinary Shares. This amount includes: (i) 510,000 Class A Ordinary Shares underlying units that were acquired by the Sponsor in a private placement effected concurrently with the closing of the Issuer’s initial public offering (“Private Placement Units”); and (ii) 1,432,500 Class B Ordinary Shares held directly by the Sponsor, which will automatically convert into Class A Ordinary Shares concurrently with or immediately following the consummation of the Issuer’s initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. This amount excludes Class A Ordinary Shares that the Reporting Persons could acquire upon exercise of warrants underlying the Private Placement Units, because such warrants are not exercisable until the later of (i) twelve (12) months from the April 6, 2022 closing of the Issuer’s initial public offering, and (ii) thirty (30) days after the completion of the Issuer’s initial business combination, and accordingly the Reporting Persons do not currently have the right to exercise the warrants.

     

    (b) Percent of class:

     

    As of August 30, 2024, the Reporting Persons may be deemed the beneficial owners of approximately 65.6% of the Class A Ordinary Shares outstanding. This percentage is based on the sum of: (i) 751,837 Class A Ordinary Shares outstanding as of August 19, 2024, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 19, 2024; and (ii) the 1,432,500 Class A Ordinary Shares issuable to the Reporting Persons upon conversion of the 1,432,500 Class B Ordinary Shares held directly by the Sponsor, which Class A Ordinary Shares have been added to the total Class A Ordinary Shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.

     

    (c) Number of shares as to which such person has:

     

    Sponsor and Mr. Xu

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 1,942,500

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 1,942,500

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    This Item 5 is not applicable.

     

    Item 6. Ownership of more than Five Percent on Behalf of Another Person.

     

    This Item 6 is not applicable.

     

    Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

     

    This Item 7 is not applicable.

     

    Item 8. Identification and classification of members of the group.

     

    This Item 8 is not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    This Item 9 is not applicable.

     

    Item 10. Certifications.

     

    This Item 10 is not applicable.

     

    Page 5 of 7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  September 16, 2024

     

    DENALI CAPITAL GLOBAL INVESTMENTS LLC  
         
    By: /s/ Jiandong Xu  
      Name:  Jiandong Xu  
      Title: Manager  

     

    JIANDONG XU    
         
    /s/ Jiandong Xu    

     

    Page 6 of 7

     

     

    EXHIBIT INDEX

     

    Ex.   Page No.
           
    1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 of the Schedule 13G filed by the Reporting Persons on May 16, 2023)  

     

    Page 7 of 7

     

     

    Get the next $DECA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DECA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DECA
    Financials

    Live finance-specific insights

    See more
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

      As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator

      11/6/24 12:24:36 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

      Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with

      10/28/24 6:00:00 AM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

      Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile

      10/16/24 4:00:00 AM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DECA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Denali Capital Global Investments Llc

      4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

      9/16/24 10:05:57 AM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form 4 filed by Large owner Xu Jiandong

      4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

      9/16/24 10:01:42 AM ET
      $DECA
      Blank Checks
      Finance

    $DECA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) --  Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from May 11, 2025 to June 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business

      5/9/25 4:00:00 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that on April 11, 2025, the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to extend the date by which the Company must consummate an initial business combination from April 11, 2025 to December 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to eight times by an additional one month each time (the "Extension"). The Company also announced today that on April 11, 2025, the Company deposit

      4/14/25 4:35:00 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Capital Acquisition Corp. Announces Adjournment of Extraordinary General Meeting of Shareholders to April 11, 2025 at 10:00 AM ET.

      NEW YORK, NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that the Company's Extraordinary General Meeting of Shareholders (the "Extraordinary General Meeting") was convened on April 10, 2025 at 9:00 a.m. Eastern Time and adjourned as it was deemed advisable to do so in order to provide shareholders of record with additional time to consider the proposals being voted on at the Extraordinary General Meeting as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 27, 2025..The Extraordinary General Meeting has been adjourned to Friday, April 11, 2025, at 10

      4/10/25 4:00:00 PM ET
      $DECA
      Blank Checks
      Finance

    $DECA
    SEC Filings

    See more
    • Denali Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

      4/22/25 5:10:19 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form S-4/A filed by Denali Capital Acquisition Corp.

      S-4/A - Denali Capital Acquisition Corp. (0001913577) (Filer)

      4/21/25 5:17:32 PM ET
      $DECA
      Blank Checks
      Finance
    • Denali Capital Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

      4/15/25 9:20:12 PM ET
      $DECA
      Blank Checks
      Finance

    $DECA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      12/6/24 4:17:05 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      11/14/24 5:49:50 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      11/14/24 2:35:09 PM ET
      $DECA
      Blank Checks
      Finance